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CONTEMPORARY REVIEW

Principles of Management of Severe Hyponatremia
Antonios H. Tzamaloukas, MD; Deepak Malhotra, MD, PhD; Bradley H. Rosen, DO; Dominic S. C. Raj, MD; Glen H. Murata, MD;
Joseph I. Shapiro, MD

H

yponatremia represents a serious health hazard.1
Hospitalized patients,2 nursing home residents,3
women,4,5 and children6 exhibit high frequency and/or
severity of hyponatremia. Hyponatremia developing during
the course of other morbid conditions increases their
severity.7–10 Estimates of direct costs for treating hyponatremia in the United States ranged between $1.61 and $3.6
billion.11
Clinical manifestations of hyponatremia are universal12,13
and range from subtle (disturbances of balance, problems in
cognition detected only during speciﬁc testing) to lifethreatening manifestations of increased intracranial pressure
with life-threatening hypoxia14–16 and noncardiac pulmonary
edema.17 Although the treating physicians must make an
accurate diagnosis based on well-established and described
clinical criteria,1 treatment is also guided by the severity of
these manifestations. The magnitude and rate of increase in
serum sodium concentration ([Na]) during treatment are
critical. Overcorrection of chronic hyponatremia may lead to
osmotic myelinolysis,18–21 whereas undercorrection may fail
to prevent life-threatening manifestations.1,22
The mainstays of treatment are restricted free water
intake and saline infusion, with or without furosemide.
There are 2 indications for saline infusion in hyponatremia.
Overt manifestations of hyponatremia are treated with
hypertonic saline, whereas symptomatic hypovolemia associated with hyponatremia without overt symptoms is usually
treated with isotonic saline.23,24 In both situations, the
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infusion of saline results in rising [Na]. This rise can be
slower or faster than desired, with potentially dire clinical
consequences.1,25
To achieve the desired rise in [Na], several formulas, most
often the Adrogue–Madias formula,23 are used to calculate
volume, rate, and strength of saline infusion. The predictive
accuracy of the Adrogue–Madias formula is, in general,
good.26 However, the rise in [Na] exceeds the value predicted
by this formula in some instances, particularly in patients with
hypovolemic hyponatremia.26,27
This report presents the principles of management of
hyponatremia with saline infusion. We analyzed factors that
cause deviations in the change of [Na] from the predicted
values. We present a clinical protocol for managing hyponatremia with saline infusion based on this analysis.

Management Principles
Figure 1 shows the application of the principles of management in a ﬂow diagram. All principles are critical for optimizing
successful patient outcomes. The principles addressing
diagnosis are covered elsewhere.1,15,16,20 We have chosen
to focus on the principles addressing the quantitative aspects
of management in this report.

Pathogenetic Mechanism, Chronicity
Establishing the pathogenetic mechanism of hyponatremia
requires a detailed history that includes medications and
drinking habits, physical examination with emphasis on
neurological and respiratory signs and on volume status,
and serum plus urine laboratory testing. The ﬁrst step in the
differential diagnosis consists of eliminating hypertonic hyponatremia and pseudohyponatremia.1,15,23,28
True (hypotonic) hyponatremia results from inability to
excrete water loads, usual or excessive. Serum vasopressin is
higher than is appropriate for the [Na] in most instances.29
Hyponatremia with inappropriately high serum vasopressin
levels can be hypovolemic (ie, body water losses relatively
lower than sodium losses), euvolemic (ie, body water excess
often with some sodium loss), or hypervolemic (ie, water gain
in excess of sodium gain).29
Journal of the American Heart Association
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Hyponatremia is considered as severe if [Na] is <115 or
110 mmol/L.34 In addition, all cases of hyponatremia treated
with hypertonic or isotonic saline infusion, including hypovolemia with hyponatremia and absence of overt neurological
manifestations, should be considered as severe because of
the risks from saline infusion. Saline infusion for hypovolemic
hyponatremia carries arguably the highest risk of inadvertently rapid rise in[Na].

Target Serum Sodium Concentration

Figure 1. Clinical approach to hyponatremia shown as a ﬂow
diagram after initial presentation. Note that the authors recommend
making an initial diagnosis and choice of therapy within 2 to 3 hours
after presentation with careful monitoring and therapeutic adjustments made thereafter.

Hypovolemic hyponatremia presents special challenges.
Previous diagnosis of a hypervolemic state, such as congestive heart failure, complicates the diagnosis. The pattern of
urinary chemistries (low sodium concentration and high
osmolality) is indistinguishable between hypovolemic hyponatremia from extrarenal causes and hypervolemic hyponatremia.29 Both conditions lead to vasopressin secretion.30 The
differential diagnosis is based on careful history and clinical
examination. Cautious volume replacement may help when
the diagnosis of hypovolemia is doubtful. Thirst from hypovolemia may increase the water load, and alterations in renal
circulation may contribute to the decreased renal ability to
excrete water.
From a pathophysiological perspective, the loss of brain
organic osmolytes occurs with greater chronicity of hyponatremia.31,32 Unfortunately, this cannot be determined using
existing clinical tools, but a recognition of this fact is essential
in understanding potential deleterious aspects of treatment.
History, prior measurements of [Na], and the neurological
picture at presentation are the only available clinical criteria
for determining chronicity. Acute hyponatremia exhibits
pronounced brain cell swelling and more severe symptoms
but lower risk of osmotic myelinolysis after rapid correction of
the [Na], compared with chronic hyponatremia with a similar
[Na] value. It is believed that the risk of myelinolysis is
greatest where organic osmolyte recovery lags,31 and in
humans, this area is usually the pons. However, chronic
hyponatremia can cause severe neurological manifestations.33 When doubt exists, it is safer to consider hyponatremia as chronic.
DOI: 10.1161/JAHA.112.005199

The targeted rise in [Na] depends on the perceived urgency of
treatment. In patients with pronounced hyponatremic symptoms, regardless of chronicity, a rapid rise of 4 to 6 mEq/L is
recommended.35 Further rises may be required if symptoms
persist after the initial rise in [Na]. For chronic hyponatremia,
previous recommendations set a maximal rate of rise in [Na]
at 12 mEq/L in the ﬁrst 24 hours and a maximal ﬁnal [Na] of
125 to 130 mEq/L.34 Because osmotic myelinolysis was
observed in patients achieving the desired rate of rise in
[Na],36 the current target rise in [Na] is set at 6 to 8 mEq/L in
24 hours, 12 to 14 mEq/L in 48 hours, and 14 to 16 mEq/L
in 72 hours.35 Prevention of hypernatremia during treatment
of hyponatremia is imperative.37

Sodium Concentration and Volume of Infused
Saline
Table 1 shows the symbols for volumes and concentrations
used in this report. Sodium concentration in commercial
saline solutions represents 2 hypertonic (0.855 and
0.513 mol/L), 1 “isotonic” (0.154 mol/L), and 3 “hypotonic”
(0.130, 0.077, and 0.034 mol/L) values.23 Sodium concentration in the infusate is usually 0.513 mol/L for hyponatremia with pronounced symptoms35 and 0.154 mol/L for
volume replacement in patients with symptomatic hypovolemia.29
The sodium concentration in the infusate should not be
limited by the strength of the commercial saline solutions.
Mixing of saline and dextrose in water can produce any
desired sodium concentration by the use of formula 1
(Table 2), which can be of help in hypovolemic hyponatremia
with minimal hyponatremic symptomatology, when a large
volume of infusate must be reconciled with the need to
produce only a modest rise in [Na]. A suitable sodium
concentration of the infusate in this instance could be the
target [Na] at 24 hours. For example, the target [Na] at
24 hours would be 117 mEq/L in a patient with hypovolemic
hyponatremia and initial [Na] of 111 mEq/L. By formula 1, the
addition of 0.316 L of dextrose in water to 1 L of 0.154 mol/L
Journal of the American Heart Association
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contributions to these differences by various factors affecting
the accuracy of the predictive formulas, Table 3 presents
details of a patient with hypovolemic hyponatremia who
developed after saline infusion overcorrection of [Na] and
osmotic myelinolysis. A slice of this patient’s brain magnetic
resonance image is shown to illustrate this myelinolysis
(Figure 2).

Symbol

Interpretation

VD5W

Volume of 5% dextrose in water

VInf

Volume of infused saline

VLost

Volume of water lost externally through the skin, the
respiratory system, the gastrointestinal system, and
the lungs

TBWI

Initial (preinfusion) total body water

Estimates from various formulas

[Na]Inf

Sodium concentration in the infusate

[Na]Ini

Initial (preinfusion) serum sodium concentration

[Na]Fin

Final (postinfusion) serum sodium concentration

[Na]Lost

Average sodium concentration in VLost (the sum of the
amounts of sodium lost through the skin,
gastrointestinal tract, and kidneys over VLost)

[K]Lost

Average potassium concentration in VLost (the fraction
amount of potassium lost though the skin,
gastrointestinal tract, and kidneys over VLost)

Nae

Total body exchangeable sodium

Ke

Total body exchangeable potassium

TBW

Total body water

[Na]pw

Sodium concentration in plasma water

For these estimates, initial [Na] was considered as equal to
111 mEq/L and initial body water as 26 L. Figure 3 shows
[Na] changes after infusion of varying volumes of saline with
varying sodium concentration predicted by formula 7. If
potassium salts are also infused, the sum of sodium plus
potassium concentration in the infusate should be substituted
for sodium concentration in formulas 6 and 7.
Table 4 shows volumes of 0.154 mol/L saline required to
raise [Na] to 117 mEq/L calculated by formulas 2, 4, and 6 in
Table 3. Formula 4 requires 5 steps to calculate a desired
volume of the infusate between 4 and 5 L. In ﬁrst step, this
calculated volume is 4.21 L by formula 6 but only 1.01 L by
formula 2. Comparison of these predictions to the ﬁndings of
Table 3 shows that formula 2 overestimated, while formulas 4
and 6 underestimated, the rise in [Na] after the ﬁrst saline
infusion.

saline produces a sodium concentration of 117 mEq/L in the
infusate.
Volume, strength, and rate of saline infused are determined by
the symptoms of hyponatremia or hypovolemia and the presenting
[Na]. In the past, the required amount and volume of hypertonic
saline were calculated by formulas 2 and 3 (Table 2), which do not
take into account the effect of infused water on the change in [Na].
The Adrogue–Madias formula23 (formula 4 in Table 2), which
calculates the predicted change in [Na] after infusion of 1 L of
saline, accounts for the major factors that determine the changes
in [Na] after the addition of saline to a closed system (initial [Na]
and body water plus sodium concentration and volume of the
infused saline). Not accounting for the water infused has caused
errors in calculations of the changes in [Na] resulting from
hypertonic infusions in experimental settings.38,39 The magnitude
of the error increased as the infused volume increased.
Although formula 4 represents a conceptual improvement
in the prediction of changes in [Na] after saline infusion, it
cannot compute directly the amount of saline required for a
desired rise in [Na] or the predicted rise in [Na] after infusion of
a volume of saline that is not a multiple of 1 L. To address these
issues, we developed formulas 5 to 7 (Table 2) accounting for
the same factors as the Adrogue–Madias formula.

Representative Patient
To illustrate quantitative differences between measured and
formula-predicted [Na] values after saline infusion and the
DOI: 10.1161/JAHA.112.005199

Pitfalls of the Formulas for Saline Infusion
The potential pitfalls of formulas 2 to 7 include inaccuracies
of estimates entered in the formulas, inaccuracies of the
formulas, and problems caused by assuming a closed
system.

Inaccuracies of estimates entered in the formulas
Among these estimates, sodium concentration in serum and
infusate and volume of infusate can be accurately measured,
but clinical estimates of body water with adjustments for
volume abnormalities1 are essentially inaccurate. Figure 4
shows that the predicted effect of widely varying estimates of
body water on the changes in [Na] after infusion of various
volumes of 0.154 mol/L saline is relatively small. After the
ﬁrst infusion of saline in the illustrative patient, predicted by
formula 7, [Na] values differed by only 0.7 mEq/L, whereas
initial body water estimates differed by 10 L; both substantially lower than the observed [Na] value (Table 3). Although
variation in the estimates of body water has a small effect on
the discrepancies between observed and predicted [Na], it is
appropriate to use in the calculations realistic values for body
water, especially in hyponatremia with pronounced hypovolemia when lower values of body water produce higher
estimates of the postinfusion [Na].
Journal of the American Heart Association
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Table 2. Formulas
Volume of 5% dextrose that needs to be added to 1 L of 0.154 mol/L saline to produce a desired sodium concentration, <154 mEq/L, of the infusate:

VD5 W ¼

154
1
½NaInf

(1)

Required amount of saline, older formula
V Inf  ½NaInf ¼ ð½NaFin  ½NaIni Þ  TBWIni

(2)

Required volume of infusate, older formula
V Inf ¼

ð½NaFin  ½NaIni Þ  TBWIni
½NaInf

(3)

The Adrogue–Madias formula15
½NaFin  ½NaIni ¼

½NaFin  ½NaIni
TBWIni þ 1

(4)

Sodium conservation with infusion of any amount of saline into a closed system:
TBWIni  ½NaIni þ V Inf  ½NaInf ¼ ðTBWIni þ V Inf Þ  ½NaFin

(5)

Required saline volume (new formula derived from formula 5):
V Inf ¼ TBWIni 

½NaFin  ½NaIni
½NaInf  ½NaFin

(6)

Final [Na] (new formula derived from formula 5)*:
½NaFin ¼

TBWIni  ½NaIni þ V Inf  ½NaInf
TBWIni þ V Inf

(7)

The Edelman formula15
½Napw ¼ 25:6 þ 1:11 

Nae þ Ke
TBW

(8)

Final serum sodium concentration after correction for the osmotic coefﬁcient of infused nonisotonic saline and for external
losses of water and electrolytes:
½NaFin ¼

TBWIni  ½NaIni þ 1:11  V Inf  ½NaInf  V Lost  ð½NaLost þ ½KLost Þ
TBWIni þ V Inf  V Lost

(9)

VD5W indicates volume of 5% dextrose in water; [Na]Inf, sodium concentration in the infusate; VInf, volume of infused saline; [Na]Fin, ﬁnal (postinfusion) serum sodium concentration; [Na]Ini,
initial (preinfusion) serum sodium concentration; TBWIni, initial (preinfusion) total body water; [Na]pw, sodium concentration in plasma water; VLost, volume of water lost externally; [Na]Lost,
average sodium concentration in VLost; [K]Lost, average potassium concentration in VLost.
*If the infused volume is 1 L, the Adrogue–Madias formula is derived by subtracting [Na]Ini from the expression of [Na]Fin in formula 7.

Inaccuracies of predictive formulas
Formulas 2 to 7 do not take into account several factors
potentially affecting [Na], including changes in body content
of solutes other than sodium or potassium, in exchangeable
DOI: 10.1161/JAHA.112.005199

potassium and sodium from body pools not readily available
for rapid changes in osmolality, in plasma water content, and
in the osmotic coefﬁcients of sodium and potassium salts,
plus effects of the Gibbs–Donnan equilibrium.40 Kurtz and
Journal of the American Heart Association
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Table 3. Representative Patient With Hypovolemic
Hyponatremia

Baseline

TBWIni,* L

26

TBWIni,†

36

L

First
Infusion

Second
Infusion

VInf, 0.154 mol/L saline, L

1.75

0.75

Infusion duration, h

6

12

120.0

129.0

Predicted [Na]Fin,* mEq/L

121.4

125.8

Predicted [Na]Fin,*§ mEq/L

113.7

114.8

118.5

121.7

[Na]Ini, mEq/L

111.0

Actual [Na]Fin, mEq/L
‡

Predicted [Na]Fin,
Predicted [Na]Fin,

†‡
†§

mEq/L
mEq/L

Predicted [Na]Fin,*§¶ mEq/L

113.0

113.8

116.0

117.5

The patient was a man with left above the knee amputation; at presentation, age
55 years, height 157.5 cm, weight 60 kg. TBWIni indicates initial (preinfusion) total body
water; VInf, volume of infused saline; [Na]Ini, initial (preinfusion) serum sodium
concentration; [Na]Fin, ﬁnal (postinfusion) serum sodium concentration; GI,
gastrointestinal.
*TBWIni calculated from the anthropometric anthropometric Watson formula40 corrected
for the effects of above-the-knee amputation41,42 and for the magnitude of volume
depletion estimated from the change in serum albumin concentration before and after
treatment.43
†
TBWIni calculated as 60% of presenting weight.
‡
From formula 2 solved for [Na]Fin.
§
From formula 7.
¶
From formula 9, assuming that (1) respiratory loss of oxygen was doubled from normal
because of the persistent hyperventilation (arterial PCO2 was in the range of 20 to
22 mm Hg in 3 measurements during the ﬁrst 3 days of hospitalization), rising the
estimated loss of water during the ﬁrst infusion of saline through the lungs, skin and GI
tract from 0.188 to 0.288 L) and (2) losses through the skin, gastrointestinal tract, and
kidneys were negligible. Urine sodium concentration was 10 mEq/L and urine osmolality
was 74 mOsm/kg at the end of the ﬁrst infusion.

Figure 2. Computed tomographic imaging brain slice from index
patient showing myelinolysis in pons (white arrow).
DOI: 10.1161/JAHA.112.005199

Figure 3. Serum sodium concentration changes ([Na]) after infusion of 1.75 L of saline with varying sodium concentration in a
patient with initial body water of 26 L and initial [Na] of 111 mEq/L.
The changes in [Na] were computed by formula 7 of this report.
Nguyen40 suggested that the cumulative effects of all the
inﬂuences on sodium concentration in plasma water are
shown in the formula of Edelman41 (formula 8 in Table 2). The
effects on [Na] of these other factors can be substantial in
states other than true hyponatremia, such as in hypertonic
hyponatremia.42 Areas requiring exploration are slow changes
in cell volume after rapid osmotic changes43 and changes in
body sodium pools not readily available for osmotic regulation43–45 and in intracellular solutes other than sodium or
potassium induced by potassium deﬁcits.46

Problems caused by assuming a closed system
Formulas 2 to 7 do not account for changes in body sodium,
potassium, or water other than saline infusion. Under experimental conditions mimicking closed systems, formulas similar
to formula 7 predicted accurately the changes in [Na] after the
induction of hypernatremia39,47 or hyponatremia.46,48 However, patients with dysnatremia do not represent closed
systems. They exhibit external losses of solute and water
during treatment. The magnitude of these losses, which are
usually hypotonic, varies depending on the pathogenetic
mechanisms of the dysnatremia, the effects of treatment on
these mechanisms, and other conditions present.
Losses occur through the respiratory system, the skin, the
gastrointestinal track and the kidneys. Normally, average loss
of water though the ﬁrst 3 routes is 1100 mL (400 mL
through the lungs, 500 mL through the skin, and 200 mL
through the gastrointestinal system), whereas water generation from oxidation amounts to 350 mL per 24 hours. Net
water loss amounts to 750 mL per 24 hours or 188 mL per
6 hours.49 Loss of solute through the 3 routes is proportionally lower than water loss. Sodium concentration in sweat is
Journal of the American Heart Association
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Formula 4 Δ[Na],* mEq/L

Formula 4 [Na]Fin, mEq/L

1

154111
26þ1

1.593

112.693

2

154112:693
27þ1
154114:072
28þ1
154115:450
29þ1
154116:735
30þ1

1.479

114.072

1.377

115.450

1.285

116.735

1.202

117.937

Formula 4 VInf, L

3
4
5

Formula 4 Calculation

Formula 6 VInf, L

Formula 3 VInf, L

26ð117111Þ
154117 ¼ 4:22

26ð117111Þ
¼ 1:01
154

*Change in Na Concentration. VInf indicates volume of infused saline; [Na]Fin, ﬁnal (postinfusion) serum sodium concentration.

30 to 65 mEq/L.49 In the stool, average sodium concentration is 40 mEq/L, and potassium, 90 mEq/L.50 Water and
solute losses increase in sweating, vomiting, or diarrhea and
hyperpnea. Urinary losses vary during treatment of hyponatremia. After correction of uncomplicated hypovolemia, urine
ﬂow increases as the volume stimulus for vasopressin
secretion disappears and water diuresis ensues. Overcorrection of hyponatremia may follow.25–27
Formula 9 in Table 2 calculates the ﬁnal [Na] in patients
infused with saline after correcting the osmotic coefﬁcient of
the infused saline40,41 and taking into account losses of
water, sodium, and potassium through all 4 external routes.
Formula 9 and similar formulas accounting for external
losses51,52 can be used to validate the principals involved in
their development by post facto observation, as was done
recently in experimental acute hyponatremia.53 Another use
of these formulas is in illustrating the quantitative effects of

Figure 4. Effect of varying body water estimates on the change in
serum sodium concentration of a patient with initial serum sodium
concentration ([Na]) of 111 mEq/L infused with various volumes of
0.154 mol/L saline. Calculations from formula 7 (Table 3).
DOI: 10.1161/JAHA.112.005199

each of the factors affecting the change in [Na] during saline
infusion (see later examples). However, the magnitude of
external losses cannot be predicted at the onset of treatment.
Consequently, calculation of the amount of infused saline is
done with closed systems formulas.
In the illustrative patient with initial body water of 26 L,
formula 9 computes that infusion of 1.75 L of 0.154 mol/L
saline would cause a rise in [Na] from 111 mEq/L to
116.0 mEq/L if through the lungs, skin, and gastrointestinal
tract loss of water was 0.288 mL and losses of sodium and
potassium were negligible during the ﬁrst saline infusion
(Table 3). Figure 5 shows predicted changes in [Na] from
diuresis in this patient. The direction of the change in [Na] is
determined by the sum of urine sodium and potassium

Figure 5. Effect of urine composition ([Na]U+[K]U) and ﬂow rate on
serum sodium concentration [Na] after infusion of 1.75 L of
0.154 mol/L saline in a patient with initial body water of 26 L and
[Na] of 111 mEq/L calculated from formula 9 (Table 3) if all the
other inﬂuences depicted in this formula except urinary losses result
in an [Na] of 116.0 mEq/L (Table 5). At [Na]U+[K]U=116 mEq/L,
urinary losses have no effect on [Na]. [Na] decreases if [Na]U+[K]U
>116 mEq/L and increases if [Na]U+[K]U <116 mEq/L.
Journal of the American Heart Association
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1. Evaluation of pathogenesis and chronicity
History, physical examination, temporal evolution of [Na] before
presentation
2. Establishment of indications for saline infusion—determination of
severity
Clinical manifestations of hyponatremia or [Na] <115 mEq/L
Clinical manifestations of hypovolemia
3. Collection of baseline information required for saline infusion
Body weight
Serum electrolytes, glucose, urea nitrogen, creatinine, osmolality,
albumin
Other serum values (uric acid, cortisol, thyroid hormones, etc),
as needed
Urine sodium and potassium concentrations and osmolality
4. Calculation of the volume, strength, and rate of saline infusion
using formula 6 (Table 2)
(a) For symptomatic hyponatremia: hypertonic saline
(b) For symptomatic hypovolemia with low presenting [Na]:
isotonic saline or calculation of salinity using formula 1
(Table 2)
(c) For a combination of (a) and (b): initially hypertonic saline,
followed by saline with [Na] concentration computed from
formula 1
5. Continuous monitoring throughout the infusion—intensive care unit
preferred
Clinical: neurological status, respiration, volume status every 2 to
3 hours; body weight daily, and more frequently if needed
Urine ﬂow rate: hourly
Serum: sodium and potassium every 2 to 3 hours; other values
(osmolality, urea nitrogen, glucose) as needed; creatinine daily;
albumin at the end of the infusion
Urine: sodium, potassium every 6 hours or more frequently if
urinary ﬂow rate increases during the infusion; osmolality
if needed
6. Changes in the management
Comparison of actual and predicted (from formula 7, Table 2)
[Na]Fin after each measurement of [Na]
Evaluation of causes of discrepancy (formula 9)
Addition of furosemide to the infusion, taking care that the
rate of saline infusion exceeds the rate of urine ﬂow in
patients with hypovolemic hyponatremia
Infusion of hypotonic saline or vasopressin plus water
[Na]Fin indicates ﬁnal (postinfusion) serum sodium concentration.

concentrations. Regardless of the urine volume, [Na] will be
equal to the predicted value of 116 mEq/L if the sum of urine
plus potassium concentration is equal to 116 mEq/L. For the
same urine volume, the lower the sum of urinary sodium plus
potassium, the greater the rise in [Na] will be. The volume of
urine containing 10 mEq/L each of sodium and potassium
needed to raise [Na] to 120 mEq/L after infusion of 1.75 L of
0.154 mol/L saline is 1.1 L.
Modest hypotonic urine production can cause large
underestimates of the increase in [Na] during treatment of
hyponatremia with saline. External losses, primarily though
DOI: 10.1161/JAHA.112.005199

the urine during treatment of hypovolemic hyponatremia,
represent the major pitfall of formulas 2 to 7.

Management Protocol
Table 5 summarizes the management of hyponatremia with
saline infusion. Closed system formulas (formulas 2 to 7)
provide estimates of the required saline volume and allow
comparison between desired and observed changes in [Na]
and, therefore, provide the frame for identifying the source of
their deviations and the guide for appropriate treatment
changes. The ﬁrst aim of treatment is to avoid undercorrection of hyponatremia.5 Prescription of the volume of saline
infused by formula 4 or 6 is suitable for this purpose.
Monitoring is critical when saline is infused, particularly in
hypovolemic hyponatremia in which water diuresis, overestimation of initial body water, and initial focusing on volume
rather than tonicity issues complicate the treatment. Monitoring, with reduced frequency of [Na] measurement (usually
once daily), is essential during treatment of hyponatremia
without saline infusion.
Many tests, especially urine chemistries and osmolality,
cannot be obtained rapidly from all hospital laboratories. For
this and other reasons, administration, along with saline, of
loop diuretics (eg, furosemide) to make urine free water
excretion more predictable may be helpful in managing
hypovolemic hyponatremia. Although furosemide will initially
increase urinary sodium and potassium excretion, it is reasonable to assume that the sum of urine sodium plus potassium
concentration is equal to 75 mEq/L when a furosemide
effect is present,1,54 at least until direct laboratory measurements are available. Because patients with hypovolemic
hyponatremia have reduced total body sodium and probably
water, care must be taken to replace more than the predicted
urinary electrolyte and water losses with infused saline.
Vasopressin V2 receptor antagonists may ultimately be
extremely useful for treating complicated chronic hyponatremias.55 However, it is unclear how to best use these new
agents at present. It is fair to say that the vasopressin V2
receptor antagonists appear to be very effective in the
settings of heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormone secretion and safe when administered as monotherapy.56,57 Unfortunately, these agents are
currently extremely expensive. Moreover, we would stress
that these agents should be avoided during saline infusion to
prevent the hazards of excessive water diuresis.

Conclusion
Accurate diagnosis of the cause, pathogenesis and chronicity,
and monitoring during treatment are the critical parts of the
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Table 5. Steps of the Management of Severe Hyponatremia
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CORRECTION

Principles of Management of Severe Hyponatremia

I

n the Contemporary Review by Tzamaloukas et al, “Principles of Management of Severe Hyponatremia,” which
was published online January 23, 2013 and appears with the
February 2013 issue of JAHA (J Am Heart Assoc. 2013;2:
e005199 doi: 10.1161/JAHA.112.005199), a correction was
needed.
Figure 2, which represents a computed tomography (CT)
image of the brain, was mislabeled as a magnetic resonance
image (MRI).

The legend to Figure 2, which read “Figure 2. Magnetic
resonance imaging brain slice from index patient showing
myelinolysis in pons (white arrow),” should have read: “Figure
2. Computed tomographic imaging brain slice from index
patient showing myelinolysis in pons (white arrow).”
The correction has been made to the current online version
of the article, which is available at http://jaha.ahajournals.
org/content/2/1/e005199.full.pdf+html. The authors regret
the error.

Figure 2. Computed tomographic imaging brain slice from index
patient showing myelinolysis in pons (white arrow).
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